Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26101015 | 0.86 | L3MBTL1 (0.46) | L3MBTL1RAB9AHTR2ASLC6A4KCNH2 | |
| SCHEMBL16962660 | 0.86 | L3MBTL1 (0.43) | L3MBTL1RAB9AHTR2ASLC6A4KCNH2 | |
| SCHEMBL13698776 | 0.85 | PDE2A (0.46) | L3MBTL1RAB9AHTR2APDE2AMAPT | |
| SCHEMBL5018905 | 0.84 | L3MBTL1 (0.64) | L3MBTL1RAB9AHTR2ASLC6A4KCNH2 | |
| SCHEMBL12863579 | 0.84 | HTR2A (0.42) | L3MBTL1RAB9AHTR2ASLC6A4KCNH2 | |
| SCHEMBL13130481 | 0.83 | MEN1 (0.43) | MAPTNPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL12668253 | 0.82 | CYP1A2 (0.52) | L3MBTL1HTR2ASLC6A4KCNH2PDE2A | |
| SCHEMBL23665186 | 0.78 | L3MBTL1 (0.43) | L3MBTL1HTR2ASLC6A4KCNH2PDE2A | |
| SCHEMBL12618448 | 0.78 | HTR2A (0.50) | L3MBTL1RAB9AHTR2ASLC6A4KCNH2 | |
| SCHEMBL29786769 | 0.78 | CETP (0.43) | CASRAKR1C3AKR1C2CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145369-A1 | COMPOUNDS FOR TREATMENT OF HAIR LOSS | PELAGE PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024092116-A1 | COMBINATION OF TEAD INHIBITORS AND EGFR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| WO-2023020519-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-23 | — | — | WO | disclosed |
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-7750007-B2 | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SUPERGEN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-7652023-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | MERCK & CO., INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | MERCK & CO., INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2009003998-A2 | ANTIPROLIFERATIVE COMPOUNDS BASED ON 5-MEMBERED HETEROCYCLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | WO | disclosed |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | L3MBTL1 2178/4885RAB9A 3451/4885HTR2A 2793/4885 |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | L3MBTL1 2036/4885RAB9A 2494/4885HTR2A 3435/4885 |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | L3MBTL1 1436/4885RAB9A 2864/4885HTR2A 1305/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | L3MBTL1 3224/4885RAB9A 1360/4885HTR2A 4829/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | L3MBTL1 2178/4885RAB9A 3451/4885HTR2A 2793/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | L3MBTL1 2178/4885RAB9A 3451/4885HTR2A 2793/4885 |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | L3MBTL1 1680/4885RAB9A 2906/4885HTR2A 2745/4885 |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | GCGR, GLP1R, GPR119 | L3MBTL1 4596/4885RAB9A 3427/4885HTR2A 216/4885 |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | NLRP3, NLRP1, NOD1 | L3MBTL1 4023/4885RAB9A 1871/4885HTR2A 1943/4885 |
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | L3MBTL1 776/4885RAB9A 1188/4885HTR2A 4497/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | L3MBTL1 3224/4885RAB9A 1360/4885HTR2A 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.